Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer

Berry, John; Green, Bridget J.; Matheson, David S.

doi:10.1016/0277-5379(87)90313-0

Cited by 68 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In several studies of breast cancer patients receiving TAM alone as adjuvant treatment, the percentage of NK cells increased and the cytotoxic activity of NK cells was enhanced [2,16]. Other studies in breast cancer patients with adjuvant TAM found little effect on cell-mediated immunity [12,21].…”

Section: Discussionmentioning

confidence: 99%

Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients

Sabbioni¹,

Castiglione

Hürny

et al. 1999

Supportive Care in Cancer

View full text Add to dashboard Cite

The effects and interaction of endocrine and cytotoxic adjuvant treatment on measures of cellular immunity were assessed in 41 stage I-II breast cancer patients from International Breast Cancer Study Group trials. Counts of lymphocytes and lymphocyte subsets [(T, T4, T8, B, natural killer (NK) and activated T (AT) cells] were assessed by flow cytometry immediately before adjuvant therapy at baseline and on day 1 of the 3rd cycle. Twenty-two patients received cyclophosphamide, methotrexate and 5-fluorouracil (CMF), 7 CMF and tamoxifen (TAM), and 12 TAM alone. On day 1 of the 3rd cycle the counts of total lymphocytes (P = 0.003) and all lymphocyte subsets (P<0.05) except AT cells were significantly lower than baseline in the CMF treatment group. There was no significant change in the CMF+TAM or in the TAM treatment group. The combination of CMF and TAM resulted in less pronounced decrease in lymphocyte and subset counts from baseline to day 1 of the 3rd cycle. It seems possible that there is an interaction between TAM with CMF that affects lymphocyte and lymphocyte subset counts during cytotoxic treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients

Sabbioni¹,

Castiglione

Hürny

et al. 1999

Supportive Care in Cancer

View full text Add to dashboard Cite

show abstract

“…The exact mechanism by which this occurs is at present unclear. A further non ER dependant cytotoxic action of tamoxifen appears to the drugs ability to act as a biological response modifier by enhancing natural killer cell activity [144].…”

Section: Other Anti-oestrogensmentioning

confidence: 99%

Current and Potential Chemotherapeutic Agents Used for Induction Chemotherapy in the Treatment of Breast Cancer

Smith¹,

Hutcheon²,

Heys

2000

CPD

View full text Add to dashboard Cite

A substantial proportion of breast cancers are large (<3 cm) or locally advanced (T3, T4, TXN2) at the time of initial presentation. The therapeutic goals that must be achieved in patients with such cancers are to obtain adequate local disease control so that surgery can be performed and to abolish occult distant metastases therefore improving survival. Over the past three decades conventional adjuvant chemotherapy regimens have been employed pre-operatively (neo-adjuvant or primary chemotherapy) to achieve these goals. Studies have now shown that the survival of patients who receive neo-adjuvant chemotherapy is comparable to that of those who receive the same chemotherapy regimen following surgery. It is also apparent that although clinical tumour response rates to neo-adjuvant chemotherapy may be high there is considerable scope for improvement in the corresponding pathological tumour response. Furthermore, data from major studies that have comprehensively evaluated the use of pre-operative chemotherapy now indicates that the pathological response of breast cancers following treatment is of far greater prognostic importance than the clinical response. Recent interests has focoused, therefore, on the implementation of more prolonged or dose intensive chemotherapy regimens with the aims of improving pathological response to treatment and ultimately overall survival. Newer antineoplastic agents are also becoming available that may be used alone or in combination with conventional therapies in order that tumor response may be improved. This review describes current and potential therapeutic agents that may be used for the induction therapy of breast cancer.

show abstract

“…A few reports have been published on the immunological effects of antiestrogens but the results have been somewhat contradictory. Some studies [8,25] have not shown any significant changes in the immunological variables of breast cancer patients treated with tamoxifen, while others have identified such changes in breast cancer patients [2,16] or in in vitro studies with tamoxifen [12,15].…”

Section: Introductionmentioning

confidence: 99%

The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene

Valavaara

Tuominen

Toivanen

1990

Cancer Immunol Immunother

View full text Add to dashboard Cite

The immune status of breast cancer patients was followed during antiestrogen treatment for at least 1 year or until progression of the disease. Twelve post-menopausal women with advanced estrogen-receptor-positive breast cancer were treated with a novel antiestrogen, toremifene. Immune functions were determined before the start of the treatment and at 3, 6, and 12 months. For NK cell cytotoxicity testing there were 74 healthy controls and for T cell subset measurements 28 healthy controls. No statistically significant changes in the T cell subsets or NK cell cytotoxicity were observed during treatment. However, throughout toremifene treatment patients had fewer CD4 cells (T helper lymphocytes) than did the controls. Cancer patients had higher pretreatment B cell values than the controls, P = 0.01, but during the first months of toremifene treatment B cell values decreased and remained within the normal range thereafter. A positive effect on mitogen-stimulation tests with phytohemagglutinin (PHA) and concanavalin A (ConA) was observed during the first months of treatment (P = 0.01 for PHA and 0.03 for log [ConA] and a stabilization at the higher level thereafter. These results indicate that toremifene has a stimulatory effect on cell-mediated immunity in breast cancer patients.

show abstract

Modulation of natural killer cell activity by tamoxifen in stage I post-menopausal breast cancer

Cited by 68 publications

References 18 publications

Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients

Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients

Current and Potential Chemotherapeutic Agents Used for Induction Chemotherapy in the Treatment of Breast Cancer

The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifene

Contact Info

Product

Resources

About